JA Ledermann

4.4k total citations
69 papers, 2.0k citations indexed

About

JA Ledermann is a scholar working on Oncology, Reproductive Medicine and Surgery. According to data from OpenAlex, JA Ledermann has authored 69 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 24 papers in Reproductive Medicine and 15 papers in Surgery. Recurrent topics in JA Ledermann's work include Ovarian cancer diagnosis and treatment (23 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and PARP inhibition in cancer therapy (10 papers). JA Ledermann is often cited by papers focused on Ovarian cancer diagnosis and treatment (23 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and PARP inhibition in cancer therapy (10 papers). JA Ledermann collaborates with scholars based in United Kingdom, United States and Italy. JA Ledermann's co-authors include David Sebag‐Montefiore, Helen Meadows, Rob Glynne‐Jones, John Northover, R.D. James, Susan Wan, Mark Jitlal, Rebecca Kristeleit, N. J. Mortensen and Philip Quirke and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

JA Ledermann

67 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
JA Ledermann United Kingdom 24 904 764 439 437 407 69 2.0k
George J. Olt United States 16 767 0.8× 680 0.9× 297 0.7× 497 1.1× 902 2.2× 38 2.3k
Giovanna Scarfone Italy 28 844 0.9× 771 1.0× 287 0.7× 377 0.9× 1.6k 3.8× 83 2.6k
D. Fennelly Ireland 25 1.8k 1.9× 878 1.1× 564 1.3× 417 1.0× 265 0.7× 85 2.6k
Sharadah Essapen United Kingdom 16 799 0.9× 1.1k 1.5× 498 1.1× 247 0.6× 943 2.3× 33 2.1k
Henrik Roed Denmark 22 755 0.8× 308 0.4× 525 1.2× 309 0.7× 333 0.8× 56 1.8k
Eirini Pectasides Greece 24 621 0.7× 493 0.6× 388 0.9× 617 1.4× 600 1.5× 49 1.8k
Giuseppe Roberto D’Agostino Italy 30 669 0.7× 607 0.8× 1.1k 2.5× 231 0.5× 350 0.9× 125 2.4k
Malgorzata Tuxen Denmark 18 687 0.8× 486 0.6× 282 0.6× 394 0.9× 947 2.3× 33 1.8k
Noh-Hyun Park South Korea 29 441 0.5× 297 0.4× 327 0.7× 398 0.9× 869 2.1× 77 2.1k
Frédèric Selle France 24 1.4k 1.5× 940 1.2× 599 1.4× 254 0.6× 1.1k 2.7× 127 2.4k

Countries citing papers authored by JA Ledermann

Since Specialization
Citations

This map shows the geographic impact of JA Ledermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by JA Ledermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites JA Ledermann more than expected).

Fields of papers citing papers by JA Ledermann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by JA Ledermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by JA Ledermann. The network helps show where JA Ledermann may publish in the future.

Co-authorship network of co-authors of JA Ledermann

This figure shows the co-authorship network connecting the top 25 collaborators of JA Ledermann. A scholar is included among the top collaborators of JA Ledermann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with JA Ledermann. JA Ledermann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Boer, Stephanie M. de, Melanie Powell, Linda Mileshkin, et al.. (2019). Patterns of Recurrence and Survival in the Randomized Portec-3 Trial of Chemoradiotherapy for High-Risk Endometrial Cancer. International Journal of Radiation Oncology*Biology*Physics. 105(1). S1–S2.
3.
Penson, Richard T., JA Ledermann, Christopher Brown, et al.. (2017). Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: Phase III SOLO2 trial (ENGOT Ov-21). Annals of Oncology. 28. v331–v331. 4 indexed citations
4.
McNeish, Iain A., JA Ledermann, Lisa M. James, et al.. (2014). A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. Annals of Oncology. 25(10). 1988–1995. 64 indexed citations
5.
Ledermann, JA, Timothy Perren, Andrew Embleton-Thirsk, et al.. (2013). Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial. UCL Discovery (University College London). 75 indexed citations
6.
Perren, Timothy, Jacobus Pfisterer, JA Ledermann, et al.. (2010). ICON7: A PHASE III RANDOMISED GYNAECOLOGIC CANCER INTERGROUP TRIAL OF CONCURRENT BEVACIZUMAB AND CHEMOTHERAPY FOLLOWED BY MAINTENANCE BEVACIZUMAB, VERSUS CHEMOTHERAPY ALONE IN WOMEN WITH NEWLY DIAGNOSED EPITHELIAL OVARIAN (EOC), PRIMARY PERITONEAL (PPC) OR FALLOPIAN TUBE CANCER (FTC). UCL Discovery (University College London). 34 indexed citations
7.
Ledermann, JA & Rebecca Kristeleit. (2010). Optimal treatment for relapsing ovarian cancer. Annals of Oncology. 21. vii218–vii222. 63 indexed citations
8.
Ledermann, JA. (2008). Lessons learned from a decade of clinical trials of high-dose chemotherapy in ovarian cancer. International Journal of Gynecological Cancer. 18. 53–58. 6 indexed citations
9.
Trimble, Edward L., Jamaine Davis, Kiyoshi Fujiwara, et al.. (2007). Clinical trials in gynecological cancer. International Journal of Gynecological Cancer. 17(3). 547–556. 7 indexed citations
10.
Ledermann, JA, N. Colombo, Andreas du Bois, et al.. (2003). Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial (vol 361, pg 2099, 2003). UCL Discovery (University College London). 2 indexed citations
11.
Ledermann, JA, et al.. (2001). Clinical management of ovarian cancer. New England Journal of Medicine. 345(1). 152–153. 3 indexed citations
12.
James, R.D., David Kerr, JA Ledermann, et al.. (2000). Excess treatment related deaths and impaired quality of life show raltitrexed is inferior to infusional 5FU regimens in the palliative chemotherapy of advanced colorectal cancer (CRC): Final results of MRC CR06. UCL Discovery (University College London). 17 indexed citations
13.
Ledermann, JA, T.S. Maughan, Daniel Kerr, et al.. (1999). Preliminary results of a multicentre randomised trial comparing 3 chemotherapy regimens (De Gramont, Lokich and Raltitrexed) in metastatic colorectal cancer. UCL Discovery (University College London). 41 indexed citations
14.
Ledermann, JA. (1996). Peripheral blood stem cell transplantation in common solid tumours: Passing phase or new era?. Clinical Oncology. 8(4). 209–211. 1 indexed citations
15.
Ledermann, JA, G Boxer, Rodney J. Hicks, et al.. (1994). The selection of antibodies for targeted therapy of small-cell lung cancer (SCLC) using a human tumour spheroid model to compare the uptake of cluster 1 and cluster w4 antibodies. British Journal of Cancer. 69(2). 247–252. 10 indexed citations
16.
17.
Begent, Rhj, et al.. (1990). PHASE I/II STUDY OF CHIMERIC B72.3 ANTIBODY IN RADIOIMMUNOTHERAPY OF COLORECTAL-CARCINOMA. UCL Discovery (University College London). 7 indexed citations
18.
Crawford, S. M., JA Ledermann, Wajdi Turkie, et al.. (1986). Is ectopic production of human chorionic gonadotrophin (hCG) or alpha fetoprotein (AFP) by tumours a marker of chemosensitivity?. European Journal of Cancer and Clinical Oncology. 22(12). 1483–1487. 16 indexed citations
19.
Ledermann, JA & Ali Keshavarzian. (1983). Acute pulmonary embolism following air travel. Postgraduate Medical Journal. 59(688). 104–105. 23 indexed citations
20.
Ledermann, JA, et al.. (1982). Side effects of benoxaprofen. BMJ. 284(6331). 1783–1784. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by George J. Olt Breakdown of academic impact, for papers by Giovanna Scarfone Breakdown of academic impact, for papers by D. Fennelly Breakdown of academic impact, for papers by Sharadah Essapen Breakdown of academic impact, for papers by Henrik Roed Breakdown of academic impact, for papers by Eirini Pectasides Breakdown of academic impact, for papers by Giuseppe Roberto D’Agostino Breakdown of academic impact, for papers by Malgorzata Tuxen Breakdown of academic impact, for papers by Noh-Hyun Park Breakdown of academic impact, for papers by Frédèric Selle
Rankless by CCL
2026